(Q36602257)

15 August 2017

1 reference

title

Microparticle-based technologies for vaccines (English)

1 reference

15 August 2017

Derek T O'Hagan

1

1 reference

PubMed ID

16997709

15 August 2017

Manmohan Singh

series ordinal

2

1 reference

PubMed ID

16997709

15 August 2017

Jeffrey B Ulmer

series ordinal

3

1 reference

15 August 2017

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

40

1 reference

15 August 2017

1

1 reference

15 August 2017

10-19

1 reference

Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

The influence of antigen organization on B cell responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Neutralizing antiviral B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Innate immunity together with duration of antigen persistence regulate effector T cell induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Development of adjuvant-active nonionic block copolymers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

A protein particle vaccine containing multiple malaria epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Induction of protective antiviral cytotoxic T cells by a tubular structure capable of carrying large foreign sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Biodegradable microspheres in drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Improving protein therapeutics with sustained-release formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Controlled release microparticles for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

A month-long effect from a single injection of microencapsulated human growth hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Loading of tetanus toxoid to biodegradable nanoparticles from branched poly(sulfobutyl-polyvinyl alcohol)-g-(lactide-co-glycolide) nanoparticles by protein adsorption: a mechanistic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

pH-triggered microparticles for peptide vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

DNA vaccines--designer vaccines for the 21st century

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Development of a preventive vaccine for Ebola virus infection in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Formulation of poly(D,L-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Cationic microparticles: A potent delivery system for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Cationic microparticles are a potent delivery system for a HCV DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Augmented humoral and cellular immune responses to hepatitis B DNA vaccine adsorbed onto cationic microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Formulation and characterization of poly (beta amino ester) microparticles for genetic vaccine delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Beta-amino ester polymers facilitate in vivo DNA transfection and adjuvant plasmid DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Microparticles as vaccine adjuvants and delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Polymyxin B enhances ISS-mediated immune responses across multiple species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

7 January 2021

HIV and mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Safety studies of the intraperitoneal injection of E1A--liposome complex in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Ambiguities in the preclinical quality assessment of microparticulate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Comparison of in vitro and in vivo methods to study stability of PLGA microencapsulated tetanus toxoid vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Formulation aspects of biodegradable polymeric microspheres for antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

A single-step immunization by sustained antigen release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Optimism over vaccines administered via mucosal surfaces.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Microparticles and polymers for the mucosal delivery of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Microparticles for intranasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Protection against vaginal SIV transmission with microencapsulated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Biologically erodable microspheres as potential oral drug delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Oral vaccination in man using antigens in particles: current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Recent advances in vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

7 January 2021

Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

7 January 2021

Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

7 January 2021

Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.017

7 January 2021

10.1016/J.YMETH.2006.05.017

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16997709